Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VR-Based Mindfulness as an Adjunct to Esketamine in Treatment-Resistant Depression
NCT07422519Recruiting
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Randomised trial in major depressive disorder (MDD) (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 54 weeks. Started Sep 2025; status: recruiting.
02
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07422519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07422519.